Caroline M. Emery

发表

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

Keith L. Ligon, Sandro Santagata, Mark A. Rubin, 2009, PloS one.

COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

Marc Vidal, Reinhard Dummer, William C. Hahn, 2010, Nature.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Paul Shapiro, Alex M Aronov, Mark Namchuk, 2017, Molecular Cancer Therapeutics.

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity

Joshua M. Korn, J. Korn, G. Caponigro, 2017, Molecular Cancer Research.

Running Title : Characterizing BRAF Inhibitor-associated MEK Mutants Corresponding

Joshua M. Korn, J. Korn, G. Caponigro, 2017 .

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

C. Emery, S. Roman-Roman, Ensar Halilovic, 2016, Oncotarget.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Nikhil Wagle, Levi A Garraway, William C Hahn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MEK1 mutations confer resistance to MEK and B-RAF inhibition

W. Sellers, L. Garraway, L. Macconaill, 2009, Proceedings of the National Academy of Sciences.

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

C. Emery, D. Porter, Q. Wu, 2014, Oncogene.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Manish R. Patel, R. Sullivan, K. Flaherty, 2017, Cancer discovery.

Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages

J. Lehár, W. Sellers, J. Korn, 2015, PloS one.

Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages

J. Lehár, W. Sellers, J. Korn, 2016, PLoS ONE.

High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007, Nature Genetics.

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007 .

C-RAF mutations confer resistance to RAF inhibitors.

L. Garraway, C. Emery, Caroline M. Emery, 2013, Cancer research.

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).

M. Burkard, M. Pishvaian, W. Ma, 2022, Journal of Clinical Oncology.

COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

T. Golub, W. Hahn, H. Hieronymus, 2010, Nature.